TCGA-CV-7440-01A-11R-2132-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.154109589
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.590
- MYC_TARGETS_V1+0.540
- E2F_TARGETS+0.420
- G2M_CHECKPOINT+0.410
- MITOTIC_SPINDLE+0.360
- ANDROGEN_RESPONSE+0.350
- TGF_BETA_SIGNALING+0.340
- UNFOLDED_PROTEIN_RESPONSE+0.320
- MTORC1_SIGNALING+0.310
- TNFA_SIGNALING_VIA_NFKB+0.290
Top 10 suppressed
- MYOGENESIS-0.230
- WNT_BETA_CATENIN_SIGNALING-0.210
- BILE_ACID_METABOLISM-0.130
- APICAL_SURFACE-0.120
- KRAS_SIGNALING_DN-0.080
- NOTCH_SIGNALING-0.080
- ESTROGEN_RESPONSE_EARLY-0.070
- XENOBIOTIC_METABOLISM-0.060
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.040
- HEME_METABOLISM-0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-H7-8502-01A-11R-2403-07 | — | — | 0.879 |
| 2 | SRR12696771 | — | — | 0.865 |
| 3 | 040cf8cf-7b9d-4873-a51d-ba13bba4201a | — | — | 0.856 |
| 4 | SRR934852 | — | — | 0.855 |
| 5 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.851 |
| 6 | SRR934804 | — | — | 0.851 |
| 7 | 266354 | EPN | EPN Tumor | 0.835 |
| 8 | BS_F6V1Y4QS | Glial-neuronal tumor NOS | — | 0.835 |
| 9 | MNG654 | — | — | 0.832 |
| 10 | 726D58A7-23E0-492A-B5CE-15DCB11B0C90 | — | — | 0.831 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 37 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.590 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.540 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.420 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.350 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.320 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.310 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.280 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.220 | Inavolisib | — uncovered |
| APOPTOSIS | 0.220 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.220 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.150 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.150 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |